1. United Kingdom Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
Smith & Nephew plc

Smith & Nephew plc

SNNUF
Smith & Nephew plcUS flagOther OTC
15.10
USD
- -
- -
12.82BMarket Cap
Smith & Nephew plc
SNNUF
(Other OTC)

Recent

price

15.10

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
4.46
4.79
4.61
4.83
5.17
3.85
5.33
5.44
5.62
5.87
5.22
5.95
5.85
6.37
6.66
7.11
5.17
Revenue per Share
0.69
0.65
0.8
0.62
0.56
0.34
0.9
0.88
0.76
0.69
0.51
0.6
0.25
0.3
0.47
0.72
0.56
Basic EPS, GAAP
0.97
0.95
1.01
0.96
0.76
0.86
0.97
1.25
1.07
1.34
1.07
1
0.52
0.7
1.13
1.48
0.76
Free Cash Flow per Basic Share
0.15
0.16
0.21
0.27
0.28
0.23
0.32
0.31
0.37
0.36
0.38
0.38
0.37
0.38
0.37
0.38
0.28
Dividend per Share
3.42
3.87
4.47
4.11
4.29
3.25
4.74
5.15
5.5
5.75
5.88
6.16
5.83
5.83
5.95
6.34
4.29
Book Value per Share
1.4
1.87
1.82
1.93
0.3
0.38
0.41
1.03
1.52
0.9
0.99
1.35
1.11
1.28
1.38
1.5
0.3
Tangible Book Value per Share
888
891
897
901
893
1,203
876
875
872
875
873
876
892
871
873
867
893
Basic Weighted Avg Shares
3,962
4,270
4,137
4,351
4,617
4,634
4,669
4,765
4,904
5,138
4,560
5,212
5,215
5,549
5,810
6,164
4,617
Sales/Revenue/Turnover
23.52
21.5
22.21
20.27
19.38
13.55
19.32
19.73
20.33
19.27
6.47
13.09
12.16
11.17
14.8
13.9
19.38
Operating Margin (%)
273
297
312
361
427
493
463
447
435
502
545
563
548
527
555
574
427
Depreciation Expense
615
575
721
556
501
410
784
767
663
600
448
524
223
263
412
625
501
Net Income, GAAP
31.28
31.63
33.97
30.67
29.83
26.65
26.18
12.74
15.11
19.25
- -
10.58
5.11
9.31
17.27
19.77
29.83
Effective Tax Rate (%)
15.52
13.47
17.43
12.78
10.85
8.85
16.79
16.1
13.52
11.68
9.82
10.05
4.28
4.74
7.09
10.14
10.85
Profit Margin (%)
1,240
1,067
1,214
1,183
1,278
1,131
1,181
1,385
1,612
1,655
2,976
2,293
2,141
1,759
2,890
2,508
1,278
Working Capital
642
16
430
347
1,666
1,434
1,564
1,423
1,301
1,975
3,353
2,848
2,712
2,319
3,258
3,177
1,666
LT Debt
2,773
3,187
3,884
4,047
4,040
3,966
3,958
4,644
4,874
5,141
5,279
5,568
5,259
5,217
5,265
5,289
4,040
Total Equity
17.9
17.15
14.94
13.52
11.98
7.97
11.65
13.62
13.27
11.53
- -
6.71
6.93
6.71
8.25
7.84
11.98
Return on Invested Capital (%)
18.14
15.79
17.62
13.31
11.06
8.35
14.9
14.04
11.83
9.9
- -
6.91
3.68
4.79
6.61
8.87
11.06
Return on Capital (%)
22.09
17.73
19.33
14.42
13.29
10.58
19.44
17.72
14.24
12.21
8.82
9.95
4.21
5.12
8.02
11.69
13.29
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Jun'14
Sep'14
Dec'14
ST Debt
65
91
39
LT Borrowings
1,986
1,936
1,656
LT Finance Leases
- -
- -
10
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
894
894
894
Market Capitalization
12,620
12,727
13,247

Working Capital

FRC

•

in mil. unless spec.
Jun'14
Sep'14
Dec'14
Total Current Assets
2,532
2,529
2,440
Cash, Cash Equivalents & STI
140
147
93
Accounts Receivable, Net
1,207
1,173
968
Inventories
1,185
1,209
1,181
Total Current Liabilities
1,148
1,228
1,162
Payables & Accruals
- -
- -
- -
ST Debt
65
91
39
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
3.07%
0.1%
0.46%
Free Cash Flow
7.13%
13.92%
30.19%
Net Income, GAAP
12.65%
17.16%
51.7%
Sales/Revenue/Turnover
3.08%
6.31%
6.09%
Total Cash Common Dividend
- -
- -
0.92%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
5,549
2024
- -
- -
- -
- -
5,810
2025
- -
- -
- -
- -
6,164

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.3
2024
- -
- -
- -
- -
0.47
2025
- -
- -
- -
- -
0.72

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.38
2024
- -
- -
- -
- -
0.37
2025
- -
- -
- -
- -
0.38
Similar Companies
NewCardio, Inc. (NWCI)
Bionovate Technologies Corp (BIIO)
Southwestern Medical Solutions, Inc. (SWNM)
IsoPlexis Corporation (ISO)
Sectra AB (publ) (0A0L.IL)
InnoCare Optoelectronics Corporation (6861.TW)
Business
Smith & Nephew plc is a global medical technology company specializing in the development, manufacture, marketing, and sale of advanced medical devices focused on the repair, regeneration, and replacement of soft and hard tissue. The company operates primarily through three global business segments: Advanced Wound Management, Sports Medicine & ENT, and Orthopaedics. Its core products include advanced wound dressings and negative pressure wound therapy systems for wound management; joint replacement devices, bone cement, and fixation products for orthopedic reconstruction; and arthroscopy tools and soft tissue repair solutions for sports medicine. The company also provides medical education, service programs, and digital ordering solutions such as its FORMEO web-based platform aimed at healthcare professionals. Smith & Nephew serves a broad international market with operations in over 100 countries. Founded in 1856 and headquartered in Watford, England, Smith & Nephew maintains major regional bases in the United States including facilities in Andover, Massachusetts for Sports Medicine & ENT, and Memphis, Tennessee for Orthopaedics. Recent major changes include the acquisition of the orthopedic extremity business from Integra in 2021, expanding its portfolio in a high-growth segment, and continued strategic focus on robotic-assisted surgery with prior acquisitions such as Blue Belt Technologies and the orthopedic joint reconstruction business unit from Brainlab. In 2025, Smith & Nephew has pursued operational improvements under a 12-point plan that has driven revenue growth and margin expansion, with raised free cash flow guidance to approximately $750 million. The company continues to invest in sustainable growth strategies, including the development of new manufacturing and R&D facilities in Melton, UK, while retaining select operations at its historic Hull site. Leadership changes include the appointment of Dr. Deepak Nath as CEO in 2022. Smith & Nephew remains committed to innovation in advanced wound care and orthopedic solutions and is preparing for a Capital Markets Day in December 2025 to outline its next phase of growth strategy. The company navigates challenges such as pricing pressures and tariffs while optimizing product portfolio sustainability, including selective market exits where profitability is limited. Smith & Nephew's extensive product range includes advanced wound management solutions like the PICO negative pressure wound therapy system, sports medicine devices including arthroscopy and ligament repair products, and orthopaedic reconstruction implants for hip, knee, and extremities, supported by digital and clinical service offerings. These integrated offerings target hospitals, outpatient surgical centers, and healthcare providers globally, reinforcing the company's position as a leader in medical technology innovation. This profile reflects Smith & Nephew's evolution as a portfolio medical technology company dedicated to improving patient outcomes through advanced wound treatment, minimally invasive surgery, and orthopedic reconstruction options on a global scale.